top of page

September 2019 // Funding

Updated: Nov 6, 2020

Synendos Therapeutics was selected for BaseLaunch Phase I and received CHF 10'000.

Recent Posts

See All

Synendos Series A Extension Synendos Therapeutics is thrilled to announce an extension to the Series A financing with the addition of Ysios Capital to its syndicate of European investors. Ysios Capita

Synendos and Prof. Jürg Gertsch received an Innosuisse Innovation Grant (total value of CHF 950’000).

bottom of page